Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib.

C SerranoS BauerD Gómez-PeregrinaY-K KangR L JonesP RutkowskiO MirM C HeinrichW D TapK NewberryA GrassianH ShiS BialickP SchöffskiM A PantaleoM von MehrenJ C TrentS George

Published in: Annals of oncology : official journal of the European Society for Medical Oncology (2023)

CtDNA sequencing efficiently detects KIT/PDGFRA mutations and prognosticates outcomes in patients with TKI-resistant GIST treated with avapritinib. ctDNA analysis can be used to monitor disease progression and provide more personalized treatment.

Keyphrases

circulating tumor
phase iii
cell free
circulating tumor cells
open label
clinical trial
phase ii
single cell
double blind
study protocol
placebo controlled
metabolic syndrome
tyrosine kinase
advanced non small cell lung cancer
adipose tissue
skeletal muscle